Anti-TACE [D1 (A12)]

Absolute Antibody

Anti-TACE [D1 (A12)]

9

TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule metalloprotease inhibition. Note from inventor: D1(A12) is conformation sensitive and sees only a specific form of the native enzyme (reflecting its redox state). It does not work by IHC or WB. It was designed as a potential drug, active in native situations.

Neutralisation/Blocking

Research Use Only

Monoclonal

D1 (A12)

ADAM17

ADAM metallopeptidase domain 17

ADAM18, CD156B, CSVP, NISBD, NISBD1, TACE, disintegrin and metalloproteinase domain-containing protein 17, ADAM metallopeptidase domain 18, TNF-alpha convertase, TNF-alpha convertase enzyme, TNF-alpha converting enzyme, a disintegrin and metalloproteinase 17, cartilage snake venom-like protease, snake venom-like protease, tumor necrosis factor, alpha, converting enzyme

Human

Disintegrin and metalloproteinase domain-containing protein 17

-20°C,2°C to 8°C

12352203